Abstract
Insulin-like growth factor-1 (IGF-1) leads via its receptor IGF-1R to the activation of the PI3K/Akt pathway, providing antiapoptotic signals to pre-malignant and malignant cells. In pancreatic cancer, IGF-1 and its receptor are constitutively overexpressed. Mammalian target of rapamycin (mTOR) is the main mediator of mitogenic stimuli transduced by PI3K/Akt. Interestingly, inhibition of mTOR activates PI3K/Akt by up-regulating IGF-1R signaling. Several targeted agents have been developed to inhibit the activity of IGF-1 or to block IGF-1R. These pharmaceuticals may offer additional ways of stimulating apoptosis in neoplastic cells. Yet, there are difficulties in targeting this pathway: The ideal anti-cancer drug target is expressed only in cancer cells; however, IGF-1 and its receptor IGF-1R are ubiquitously expressed throughout the body. Moreover, when using antibodies against IGF-1R, the structurally similar insulin receptor might also be blocked, leading to hyperglycemia as a severe side effect. There are currently several phase I/II trials investigating IGF-1 and its receptor as a drug target in various kinds of cancer. Specifically, therapeutic effects on pancreatic cancer by combining a humanized monoclonal antibody against IGF-1R with other chemotherapeutics are being investigated. To improve the clinical outcome of mTOR inhibitors such as everolimus, it has been suggested to use combination therapies of mTOR inhibitors and IGF-1/IGF-1R inhibitors. In theory, this would counterbalance the feedback effects of mTOR inhibition on IGF-1 signaling. In conclusion, IGF-1 and its receptor are promising new drug targets in cancer therapy. Combination therapies of IGF-1/IGF-1R inhibitors and mTOR inhibitors could improve the clinical outcome.
Keywords: IGF-1, mTOR, chemotherapy, pancreatic cancer
Anti-Cancer Agents in Medicinal Chemistry
Title: Insulin-Like Growth Factor Signaling as a Therapeutic Target in Pancreatic Cancer
Volume: 11 Issue: 5
Author(s): Simon Rieder, Christoph W. Michalski, Helmut Friess and > Kleeff
Affiliation:
Keywords: IGF-1, mTOR, chemotherapy, pancreatic cancer
Abstract: Insulin-like growth factor-1 (IGF-1) leads via its receptor IGF-1R to the activation of the PI3K/Akt pathway, providing antiapoptotic signals to pre-malignant and malignant cells. In pancreatic cancer, IGF-1 and its receptor are constitutively overexpressed. Mammalian target of rapamycin (mTOR) is the main mediator of mitogenic stimuli transduced by PI3K/Akt. Interestingly, inhibition of mTOR activates PI3K/Akt by up-regulating IGF-1R signaling. Several targeted agents have been developed to inhibit the activity of IGF-1 or to block IGF-1R. These pharmaceuticals may offer additional ways of stimulating apoptosis in neoplastic cells. Yet, there are difficulties in targeting this pathway: The ideal anti-cancer drug target is expressed only in cancer cells; however, IGF-1 and its receptor IGF-1R are ubiquitously expressed throughout the body. Moreover, when using antibodies against IGF-1R, the structurally similar insulin receptor might also be blocked, leading to hyperglycemia as a severe side effect. There are currently several phase I/II trials investigating IGF-1 and its receptor as a drug target in various kinds of cancer. Specifically, therapeutic effects on pancreatic cancer by combining a humanized monoclonal antibody against IGF-1R with other chemotherapeutics are being investigated. To improve the clinical outcome of mTOR inhibitors such as everolimus, it has been suggested to use combination therapies of mTOR inhibitors and IGF-1/IGF-1R inhibitors. In theory, this would counterbalance the feedback effects of mTOR inhibition on IGF-1 signaling. In conclusion, IGF-1 and its receptor are promising new drug targets in cancer therapy. Combination therapies of IGF-1/IGF-1R inhibitors and mTOR inhibitors could improve the clinical outcome.
Export Options
About this article
Cite this article as:
Rieder Simon, W. Michalski Christoph, Friess Helmut and Kleeff >, Insulin-Like Growth Factor Signaling as a Therapeutic Target in Pancreatic Cancer, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (5) . https://dx.doi.org/10.2174/187152011795677454
DOI https://dx.doi.org/10.2174/187152011795677454 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Renal Ischemia: How Commonly Does it Cause Renal Failure?
Current Hypertension Reviews The Involvement of Metallothioneins in Mitochondrial Function and Disease
Current Protein & Peptide Science Central Arterial Aging and Angiotensin II Signaling
Current Hypertension Reviews Molecular Docking, Synthesis and Biological Evaluation of Sulphonylureas/ Guanidine Derivatives as Promising Antidiabetic Agent
Current Drug Discovery Technologies Synthesized 2-Trifluoromethylquinazolines and Quinazolinones Protect BV2 and N2a Cells against LPS- and H<sub>2</sub>O<sub>2</sub>-induced Cytotoxicity
Medicinal Chemistry The Occurrence of Bisphenol A, Phthalates, Parabens and Other Environmental Phenolic Compounds in House Dust: A Review
Current Organic Chemistry Genomics and Pharmacogenomics in the Management of Breast Cancer
Current Pharmacogenomics and Personalized Medicine Curcumin Therapeutic Modulation of the Wnt Signaling Pathway
Current Pharmaceutical Biotechnology Editorial [Hot topic: Latest Development on Zinc Enzymes (Executive Editor: Georgios A. Spyroulias)]
Current Pharmaceutical Design Wound-Associated Skin Fibrosis: Mechanisms and Treatments Based on Modulating the Inflammatory Response
Endocrine, Metabolic & Immune Disorders - Drug Targets Effectiveness of a Standardized and Specific Follow-Up in Memory Centers in Patients with Alzheimer’s Disease
Current Alzheimer Research The Design of Drug Candidate Molecules as Selective Inhibitors of Therapeutically Relevant Protein Kinases
Current Medicinal Chemistry Meet the Editorial Board
Current Vascular Pharmacology Cancer Multitarget Pharmacology in Prostate Tumors: Tyrosine Kinase Inhibitors and Beyond
Current Medicinal Chemistry Stem Cell Therapies for the Treatment of Diabetic Neuropathies: Future Perspectives
Current Diabetes Reviews Therapeutic Targeting of B Lymphocyte Stimulator (BLyS) in the Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Adverse Drug Reactions in a Pulmonary Teaching Hospital: Incidence, Pattern, Seriousness, and Preventability
Current Drug Safety Galectin-9 in Cancer Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Recent Advances in the Comprehension and the Management of Perioperative Systemic Host Response During Cardiopulmonary Bypass
Recent Patents on Cardiovascular Drug Discovery In Vitro and In Vivo Sirolimus for Modulation of Allogeneic Hematopoietic Stem Cell Transplantation
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents